JP2016515532A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515532A5
JP2016515532A5 JP2016503333A JP2016503333A JP2016515532A5 JP 2016515532 A5 JP2016515532 A5 JP 2016515532A5 JP 2016503333 A JP2016503333 A JP 2016503333A JP 2016503333 A JP2016503333 A JP 2016503333A JP 2016515532 A5 JP2016515532 A5 JP 2016515532A5
Authority
JP
Japan
Prior art keywords
composition
chemically
enzymatically oxidized
oxidized synthetic
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515532A (ja
JP6670987B2 (ja
Filing date
Publication date
Priority claimed from US13/843,773 external-priority patent/US9394349B2/en
Application filed filed Critical
Publication of JP2016515532A publication Critical patent/JP2016515532A/ja
Publication of JP2016515532A5 publication Critical patent/JP2016515532A5/ja
Application granted granted Critical
Publication of JP6670987B2 publication Critical patent/JP6670987B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503333A 2013-03-15 2014-03-17 ヒトセクレトグロビンタンパク質の修飾および新規組成物 Active JP6670987B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/843,773 US9394349B2 (en) 2013-03-15 2013-03-15 Modification and compositions of human secretoglobin proteins
US13/843,773 2013-03-15
PCT/US2014/030117 WO2014145368A2 (en) 2013-03-15 2014-03-17 Modification and novel compositions of human secretoglobin proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019218277A Division JP2020055833A (ja) 2013-03-15 2019-12-02 ヒトセクレトグロビンタンパク質の修飾および新規組成物

Publications (3)

Publication Number Publication Date
JP2016515532A JP2016515532A (ja) 2016-05-30
JP2016515532A5 true JP2016515532A5 (enExample) 2017-04-20
JP6670987B2 JP6670987B2 (ja) 2020-03-25

Family

ID=51530119

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016503333A Active JP6670987B2 (ja) 2013-03-15 2014-03-17 ヒトセクレトグロビンタンパク質の修飾および新規組成物
JP2019218277A Pending JP2020055833A (ja) 2013-03-15 2019-12-02 ヒトセクレトグロビンタンパク質の修飾および新規組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019218277A Pending JP2020055833A (ja) 2013-03-15 2019-12-02 ヒトセクレトグロビンタンパク質の修飾および新規組成物

Country Status (13)

Country Link
US (4) US9394349B2 (enExample)
EP (2) EP2968449A4 (enExample)
JP (2) JP6670987B2 (enExample)
KR (1) KR20160030076A (enExample)
CN (1) CN105744946A (enExample)
AU (1) AU2014233127A1 (enExample)
BR (1) BR112015021266A2 (enExample)
CA (1) CA2907439A1 (enExample)
IL (1) IL241417A0 (enExample)
MX (1) MX2015013092A (enExample)
RU (1) RU2015144360A (enExample)
SG (1) SG11201507277YA (enExample)
WO (1) WO2014145368A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins
US12162914B2 (en) 2013-03-15 2024-12-10 Apc Research Assets Llc Modification and compositions of human secretoglobin proteins
US20180112200A1 (en) * 2014-12-22 2018-04-26 The Regents Of The University Of California Compositions and methods for generating antigens, antibodies, and immunotherapeutic compositions and methods
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Guangzhou Hanfang Pharmaceutical Co.,Ltd. シェーグレン症候群の治療におけるペオニフロリン−6’−o−ベンゼンスルホン酸の使用
JP2022509856A (ja) * 2018-11-30 2022-01-24 エーピーシー リサーチ アセッツ,エルエルシー ヘパラン硫酸プロテオグリカンタンパク質との相互作用を介してグリコカリックスを保護するためのセクレトグロビンの組成物及び使用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1006919A3 (nl) * 1993-03-15 1995-01-24 Ley Marc Jozef Philemon De Farmaceutisch preparaat op basis van clara celeiwit cc10, en het gebruik daarvan als geneesmiddel en diagnosticum.
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20040047857A1 (en) * 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
AU5551299A (en) 1998-08-13 2000-03-06 Trustees Of The University Of Pennsylvania, The Method of identifying proteins
US6953666B1 (en) 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
WO2004101824A1 (ja) 2003-05-14 2004-11-25 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の検出方法
AU2004254600A1 (en) 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
CN1580261A (zh) * 2003-08-06 2005-02-16 上海富纯中南生物技术有限公司 Cc10蛋白的制备及应用
US7318936B2 (en) 2003-11-14 2008-01-15 Alza Corporation Minimization of drug oxidation in drug irradiated excipients formulations
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
WO2008039941A2 (en) 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
US20090004684A1 (en) 2007-05-23 2009-01-01 Claudia Susanne Maier Compositions and Methods for Detection and Quantification of Protein Oxidation
EP2488205B1 (en) * 2009-10-15 2016-09-21 Clarassance, Inc. Recombinant human cc10 protein for treatment of influenza
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins

Similar Documents

Publication Publication Date Title
JP2014224126A5 (enExample)
JP2016515532A5 (enExample)
JP2015038108A5 (enExample)
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
MX389623B (es) Polipeptidos adecuados para detergente.
RU2016149463A (ru) Улучшенные вариабельные домены иммуноглобулина
JP2013523703A5 (enExample)
WO2015179635A3 (en) Ras inhibitory peptides and uses thereof
RU2015144360A (ru) Модификация и новые композиции на основе секретоглобинов человека
WO2016115257A3 (en) Plasticizers derived from polycyclic acids or dimer fatty acids
EA202092749A1 (ru) Композиции, содержащие аминокислоты, для применения в предотвращении и лечении заболеваний печени
JP2018121590A5 (enExample)
MX2020006510A (es) Peptido novedoso.
CU24609B1 (es) Proteína de fusión que comprende una proteína de subunidad de ferritina monomérica unida a una proteína de dominio alfa 3 de mic
JP2016519077A5 (enExample)
JP2015516943A5 (enExample)
WO2018115877A3 (en) Rumen derived antimicrobial peptides
MY189265A (en) Process for making mixtures of enantiomers, and mixtures of enantiomers
JP2015174855A5 (enExample)
JP2019218304A5 (enExample)
JP2017014205A5 (enExample)
JP2014201572A5 (enExample)
CY1117536T1 (el) Συνθεσεις που περιλαμβανουν αμινοξεα για τη θεραπεια της χρονιας αποφρακτικης πνευμονοπαθειας
JPWO2019168107A5 (enExample)
EP3666893A4 (en) D type amino acid dehydrogenase